Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues

~ First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery ~ No venous ulcer recurrences or CVI relapses ~ Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS)

Daniel Carlson

November 17, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.